NASDAQ:CYNO - Cynosure Stock Price, Price Target & More

$66.15 +0.15 (+0.23 %)

(As of 04/25/2018 03:00 AM ET)

Previous Close$66.00

Today's Range$66.15 - $66.15

52-Week Range$39.90 - $66.65

Volume214 shs

Average Volume1.24 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

About Cynosure (NASDAQ:CYNO)

Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Receive CYNO News and Ratings via Email

Sign-up to receive the latest news and ratings for CYNO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A

Sub-IndustryHealth Care Equipment

SectorN/A

SymbolNASDAQ:CYNO

CUSIP23257720

Webwww.cynosure.com

Phone+1-978-2564200

Debt

Debt-to-Equity Ratio0.04%

Current Ratio3.28%

Quick Ratio2.54%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins0.70%

Return on Equity0.75%

Return on Assets0.59%

Miscellaneous

Employees857

Outstanding Shares24,350,000

How to Become a New Pot Stock Millionaire

Cynosure (NASDAQ:CYNO) Frequently Asked Questions

What is Cynosure's stock symbol?

Cynosure trades on the NASDAQ under the ticker symbol "CYNO."

How were Cynosure's earnings last quarter?

Cynosure, Inc. (NASDAQ:CYNO) posted its quarterly earnings results on Tuesday, July, 26th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.07. The medical equipment provider earned $110.30 million during the quarter, compared to analyst estimates of $101.31 million. Cynosure had a return on equity of 0.75% and a net margin of 0.70%. Cynosure's quarterly revenue was up 31.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 EPS. View Cynosure's Earnings History.

Has Cynosure been receiving favorable news coverage?

Media coverage about CYNO stock has been trending positive on Wednesday, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cynosure earned a news sentiment score of 0.35 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 48.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Cynosure?

Shares of CYNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cynosure's stock price today?

One share of CYNO stock can currently be purchased for approximately $66.15.

How can I contact Cynosure?

Cynosure's mailing address is 5 Carlisle Rd, WESTFORD, MA 01886-3601, United States. The medical equipment provider can be reached via phone at +1-978-2564200.

MarketBeat Community Rating for Cynosure (CYNO)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		248 (Vote Outperform)
Underperform Votes:		137 (Vote Underperform)
Total Votes:		385

MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe CYNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYNO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cynosure (NASDAQ:CYNO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	Hold	Hold	Hold
Consensus Rating Score:	N/A	2.00	2.25	2.40
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	$66.00	$64.00	$58.40
Price Target Upside:	N/A	0.00% downside	3.03% downside	11.52% downside

Cynosure (NASDAQ:CYNO) Consensus Price Target History

Price Target History for Cynosure (NASDAQ:CYNO)

Cynosure (NASDAQ:CYNO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/28/2017	Aegis	Reiterated Rating	Hold	$66.00	N/A
2/16/2017	Northland Securities	Reiterated Rating	Outperform	$60.00	N/A
2/14/2017	Northcoast Research	Upgrade	Sell -> Neutral		N/A
2/14/2017	Maxim Group	Downgrade	Buy -> Hold	$66.00	N/A
10/28/2016	Leerink Swann	Reiterated Rating	Outperform	$63.00 -> $60.00	N/A
10/26/2016	Stifel Nicolaus	Reiterated Rating	Buy	$62.00 -> $58.00	N/A
10/24/2016	Brean Capital	Reiterated Rating	Buy		N/A

(Data available from 4/25/2016 forward)

Cynosure (NASDAQ:CYNO) Earnings History and Estimates Chart

Earnings by Quarter for Cynosure (NASDAQ:CYNO)

Cynosure (NASDAQ:CYNO) Earnings Estimates

2018 EPS Consensus Estimate: $2.02

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.34	$0.34	$0.34
Q2 2018	1	$0.51	$0.51	$0.51
Q3 2018	1	$0.50	$0.50	$0.50
Q4 2018	1	$0.67	$0.67	$0.67

Cynosure (NASDAQ CYNO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/7/2017	Q416	$0.41	$0.44	$119.97 million	$122.10 million	View	Listen
10/25/2016	Q316	$0.28	$0.29	$101.11 million	$106.40 million	View	Listen
7/26/2016	Q216	$0.29	$0.36	$101.31 million	$110.30 million	View	Listen
4/26/2016	Q116	$0.14	$0.19	$85.78 million	$94.70 million	View	Listen
2/9/2016	Q415	$0.36	$0.42	$95.01 million	$102.40 million	View	Listen
10/27/2015	Q315	$0.18	$0.21	$76.68 million	$78.40 million	View	Listen
7/28/2015	Q215	$0.27	$0.30	$82.71 million	$83.70 million	View	Listen
5/5/2015	Q1	$0.17	$0.15	$70.87 million	$74.90 million	View	Listen
2/10/2015	Q414	$0.39	$0.36	$83.01 million	$86.30 million	View	Listen
10/28/2014	Q314	$0.24	$0.25	$69.94 million	$71.50 million	View	Listen
7/29/2014	Q214	$0.30	$0.32	$71.15 million	$72.60 million	View	Listen
5/6/2014	Q1	$0.23	$0.19	$64.70 million	$62.00 million	View	Listen
2/12/2014	Q413	$0.19	$0.39	$67.80 million	$74.50 million	View	Listen
10/29/2013	Q313	$0.19	$0.23	$61.60 million	$60.70 million	View	Listen
7/31/2013	Q2 2013	$0.20	$0.29	$46.96 million	$50.09 million	View	Listen
4/30/2013	Q1 2013	$0.13	$0.12	$38.51 million	$10.70 million	View	Listen
2/12/2013	Q4 2012	$0.23	$0.27	$40.98 million	$47.70 million	View	Listen
10/23/2012		$0.12	$0.25			View	N/A
7/24/2012		$0.12	$0.20			View	N/A
5/1/2012		($0.02)	$0.06			View	N/A
2/14/2012		$0.05	$0.08			View	N/A
10/25/2011		$0.04	($0.06)			View	N/A
7/26/2011	Q2 2011	($0.03)	($0.01)			View	N/A
5/3/2011		($0.05)	($0.15)			View	N/A
2/15/2011		($0.03)	($0.06)			View	N/A
10/26/2010	Q3 2010	($0.10)	($0.04)			View	N/A
7/27/2010	Q2 2010	($0.09)	($0.12)			View	N/A
5/4/2010	Q1 2010	($0.15)	($0.22)			View	N/A
2/9/2010	Q4 2009	($0.11)	($0.16)			View	N/A
10/27/2009	Q3 2009	($0.17)	($0.15)			View	N/A
7/28/2009	Q2 2009	($0.16)	($0.18)			View	N/A
5/5/2009	Q1 2009	$0.02	($0.32)			View	N/A
2/10/2009	Q4 2008	($0.15)	($0.19)			View	N/A
10/28/2008	Q3 2008	$0.38	$0.37			View	N/A
7/29/2008	Q2 2008	$0.36	$0.36			View	N/A
4/29/2008	Q1 2008	$0.31	$0.38			View	N/A
2/12/2008	Q4 2007	$0.36	$0.41			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cynosure (NASDAQ:CYNO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cynosure (NASDAQ CYNO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.90%

Insider Trading History for Cynosure (NASDAQ:CYNO)

Cynosure (NASDAQ CYNO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/22/2016	Douglas J Delaney	VP	Sell	7,875	$45.00	$354,375.00	5,833
11/22/2016	Michael R Davin	Chairman	Sell	16,284	$45.00	$732,780.00	4,222
8/30/2016	Brian M Barefoot	Director	Sell	21,000	$51.66	$1,084,860.00	5,000
8/15/2016	Michael R Davin	Chairman	Sell	12,062	$53.35	$643,507.70	12,062
8/15/2016	Timothy W Baker	CFO	Sell	5,834	$53.35	$311,243.90	5,834
8/11/2016	Michael R Davin	Chairman	Sell	4,222	$53.18	$224,525.96	4,222
8/11/2016	Timothy W Baker	CFO	Sell	2,041	$53.19	$108,560.79	2,041
5/13/2016	Douglas J Delaney	VP	Sell	12,299	$46.60	$573,133.40	2,042
5/13/2016	Michael R Davin	CEO	Sell	26,271	$46.59	$1,223,965.89	4,221
5/13/2016	Timothy W Baker	CFO	Sell	12,451	$46.60	$580,216.60	2,042
4/18/2016	Douglas J Delaney	VP	Sell	15,890	$45.01	$715,208.90	11,807
4/18/2016	Michael R Davin	CEO	Sell	74,729	$45.31	$3,385,970.99	24,575
4/18/2016	Timothy W Baker	CFO	Sell	14,008	$45.02	$630,640.16	9,925
4/14/2016	Douglas J Delaney	VP	Sell	24,488	$45.02	$1,102,449.76	8,100
4/14/2016	Michael R Davin	CEO	Sell	61,377	$45.01	$2,762,578.77	1,604
4/14/2016	Timothy W Baker	CFO	Sell	39,857	$45.02	$1,794,362.14	8,107
4/13/2016	Michael R Davin	CEO	Sell	72	$45.00	$3,240.00	72
4/6/2016	Douglas J Delaney	VP	Sell	4,408	$45.08	$198,712.64	2,508
4/6/2016	Michael R Davin	CEO	Sell	4,869	$45.11	$219,640.59	2,969
4/6/2016	Timothy W Baker	CFO	Sell	4,413	$45.08	$198,938.04	2,520
4/4/2016	Douglas J Delaney	VP	Sell	66,626	$45.47	$3,029,484.22	7,233
4/4/2016	Michael R Davin	CEO	Sell	66,259	$45.61	$3,022,072.99	8,680
4/4/2016	Timothy W Baker	CFO	Sell	53,297	$45.60	$2,430,343.20	9,496
12/31/2015	Michael R. Davin	CEO	Sell	200	$45.00	$9,000.00
12/31/2015	Timothy W. Baker	CFO	Sell	100	$45.00	$4,500.00
6/1/2015	Ettore V Biagioni	Director	Sell	24,000	$36.25	$870,000.00
5/20/2015	Douglas J Delaney	VP	Sell	89,000	$38.01	$3,382,890.00
5/20/2015	Michael R Davin	CEO	Sell	151,000	$38.07	$5,748,570.00
4/23/2015	Michael R Davin	CEO	Sell	6,991	$33.04	$230,982.64
4/10/2015	Michael R Davin	CEO	Sell	44,677	$33.01	$1,474,787.77
4/9/2015	Douglas J Delaney	VP	Sell	28,335	$33.01	$935,338.35
4/9/2015	Michael R Davin	CEO	Sell	70,000	$32.00	$2,240,000.00
4/8/2015	Douglas J Delaney	VP	Sell	45,000	$32.00	$1,440,000.00
1/9/2015	Ettore V Biagioni	Director	Sell	12,000	$30.09	$361,080.00
12/2/2014	Ettore V Biagioni	Director	Sell	2,500	$28.00	$70,000.00
11/24/2014	Ettore V Biagioni	Director	Sell	5,000	$27.28	$136,400.00
11/5/2013	Marina Hatsopoulos	Director	Buy	3,000	$22.60	$67,800.00	3,000
9/5/2012	Douglas J Delaney	VP	Sell	16,904	$27.65	$467,395.60
9/5/2012	Michael R Davin	CEO	Sell	16,770	$27.65	$463,690.50
9/5/2012	Timothy W Baker	CFO	Sell	16,854	$27.65	$466,013.10

(Data available from 1/1/2013 forward)

Cynosure (NASDAQ CYNO) News Headlines

Source:

Date	Headline
	Global Surgical Lasers Market Opportunities 2018: Cynosure Inc., Abbott Laboratories, BISON MEDICAL Co. Ltd www.marketwatch.com - March 14 at 10:30 AM
	Head-To-Head Survey: Cynosure (CYNO) & Koninklijke Philips (PHG) www.americanbankingnews.com - February 15 at 3:18 AM
	Financial Contrast: Danaher (DHR) versus Cynosure (CYNO) www.americanbankingnews.com - January 20 at 1:16 PM
	Federal judge says jurisdiction lacking in Cynosure lawsuit www.reuters.com - January 18 at 9:49 AM
	Hologic Preliminary Revenues Increase 8% to Approximately $791 Million in the ... www.prnewswire.com - January 9 at 5:29 PM
	Restoration Robotics® Announces Appointment of Chris Aronson as Vice President of Sales - Nasdaq www.nasdaq.com - January 5 at 5:08 PM
	Contrasting Varian Medical Systems (VAR) and Cynosure (CYNO) www.americanbankingnews.com - December 29 at 3:22 PM
	Auto Sales to Advance on Strong Economy, China Growth www.zacks.com - December 20 at 5:20 PM
	Cowen: Hologic Is A Relatively Cheap Stock Overdue For Upside - Benzinga www.benzinga.com - December 11 at 5:34 PM
	Hologic (HOLX) Up 8% Since Earnings Report: Can It Continue? www.nasdaq.com - December 11 at 10:12 AM
	Non-Invasive Fat Reduction Market - Global Industry Analysis, Size, Share ... www.prnewswire.com - November 21 at 11:03 PM
	Facial Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2022 www.prnewswire.com - November 20 at 11:44 PM
	Head-To-Head Contrast: Cynosure (CYNO) versus The Competition www.americanbankingnews.com - November 19 at 11:36 AM
	Hologic (HOLX) Q4 2017 Results - Earnings Call Transcript seekingalpha.com - November 9 at 12:22 AM
	Tattoo Removal Market - Global Opportunity Analysis and Industry Forecast, 2017-2023 www.bizjournals.com - November 4 at 6:54 AM
	Head-To-Head Review: Cynosure (CYNO) versus The Competition www.americanbankingnews.com - November 2 at 11:30 AM
	Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings? www.nasdaq.com - November 1 at 6:39 PM
	Non-Surgical Skin Tightening Market to reach US$ 500 Mn by 2022 - Transparency Market Research globenewswire.com - October 25 at 7:22 PM
	Non-invasive Fat Reduction Market Worth US$2.50 Billion by 2025, Globally: Transparency Market Research www.marketwatch.com - October 25 at 7:22 PM
	Global $26.5 Billion Medical Aesthetics Market to 2024 - Research and Markets - Business Wire (press release) www.businesswire.com - October 24 at 8:07 PM
	Global Non-Surgical Fat Reduction Market to Incur Valuation of US$ 220 Mn by 2022 - Future Market Insights www.marketwatch.com - October 23 at 6:14 PM
	Facial Treatment Market to be Driven by Rising Prevalence of Dermatological Conditions globenewswire.com - October 17 at 6:33 PM
	3 Plastic & Reconstructive Surgery Stocks Looking Good - Nasdaq www.nasdaq.com - October 12 at 11:34 PM
	3 Plastic & Reconstructive Surgery Stocks Looking Good finance.yahoo.com - October 11 at 7:12 PM
	Critical Review: Cynosure (CYNO) versus Intuitive Surgical (ISRG) www.americanbankingnews.com - October 1 at 4:38 PM
	Hologic (HOLX) Granted FDA 510(k) Clearance to Market SculpSure for Non-Invasive Body Contouring (Lipolysis) of the Submental Area www.streetinsider.com - September 27 at 6:50 PM
	Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive ... www.prnewswire.com - September 27 at 6:50 PM
	Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin) www.bizjournals.com - September 27 at 6:50 PM
	Cosmetic Procedures Market to Reach US$ 51.6 Billion by 2022 – Persistence Market Research globenewswire.com - September 27 at 6:50 PM
	Trump's Pick for Federal Reserve's Top Regulator Just Won This Battle www.thestreet.com - September 8 at 6:07 PM
	Cutera Strengthens Leadership Team with Two Key Executive Appointments - Nasdaq www.nasdaq.com - August 21 at 10:26 PM
	Global Aesthetic Laser Market 2017-2023 - Leading Companies Cynosure, Lumenis, Cutera, Alma Lasers & Sciton - Research and Markets www.businesswire.com - August 19 at 4:57 PM
	Global Aesthetic Laser Market 2017-2023 - Leading Companies ... - Business Wire (press release) www.businesswire.com - August 18 at 5:44 PM
	Analyzing Derma Sciences (DSCI) & Cynosure (CYNO) www.americanbankingnews.com - August 3 at 8:29 AM
	Hologic (HOLX) Q3 2017 Results - Earnings Call Transcript seekingalpha.com - August 2 at 11:37 PM
	Hologic Announces Financial Results for Third Quarter of Fiscal 2017 www.bizjournals.com - August 2 at 6:37 PM
	Trump's Wall Street Watchdogs to Shed Millions Invested in Banks - Bloomberg www.bloomberg.com - July 25 at 5:42 PM
	What's in the Offing for Hologic (HOLX) in Q3 Earnings? - Nasdaq www.nasdaq.com - July 24 at 10:46 AM
	Medical Aesthetics Market to Reach $19.4 Billion by 2023: P&S Market Research globenewswire.com - July 19 at 11:56 PM
	Hologic: Growth Cheaply Priced - Seeking Alpha seekingalpha.com - July 16 at 9:42 AM
	Revolving Door Spins Ex-Carlyle Deal-Maker Into Key Fed Role www.bloomberg.com - July 12 at 11:27 PM
	Trump's Fed Nominee Has History of Benefiting From Bailouts - New York Times www.nytimes.com - July 12 at 6:24 PM
	Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure ... www.prnewswire.com - June 15 at 6:33 PM
	Global Cellulite Treatment Market - Industry Forecast to 2025 - Analysis By Treatment, End User & Geography - Research and Markets www.finanznachrichten.de - June 8 at 5:39 PM
	Global Anti-Aging Market Size & Trends Will Reach $216.52 Billion by 2021: Zion Market Research www.benzinga.com - June 5 at 11:54 AM
	Global Medical Aesthetics Market to Reach $13 Billion by 2021 - Analysis By Product, End User & Region - Research and Markets www.finanznachrichten.de - May 29 at 4:45 PM
	Asia-Pacific Aesthetic Lasers and Energy Devices Market Outlook to 2023 www.bizjournals.com - May 16 at 4:39 PM
	Medical Aesthetic Devices Market - Middle East and North Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 www.prnewswire.com - May 11 at 10:18 PM